https://doi.org/10.55788/dfff4f39
“Post-operative recurrence of CD is the standard and not an exception,” stated Dr Eline van der Does de Willebois (Amsterdam University Medical Centers, the Netherlands) [1]. “We should therefore aim to investigate options to prevent post-operative recurrence of CD following ileocolic resection.” It is somewhat unclear whether an extended mesenterectomy or a mesenteric-sparing approach yields better outcomes. It has been suggested that the mesentery could be a driver of disease, whereas others think that the mesentery might be a protective contributor [2,3].
To gain an evidence-based perspective on this matter, the double-blinded, international SPICY trial (NCT04538638) randomised 139 patients with CD undergoing primary ileocolic resection 1:1 to extensive mesenteric resection following the lower border of the ileocolic trunk or mesenteric-sparing ileocolic resection, as is currently advised by guidelines [1]. The primary endpoint was endoscopic recurrence at 6 months after the procedure, defined as a modified Rutgeerts score ≥i2b.
Endoscopic recurrence was reported in 42.4% of the participants in the extended mesenterectomy arm and in 43.1% of the participants in the mesenteric-sparing arm, revealing no clear difference between both arms. Dr van der Does de Willebois added that anastomotic leakage was numerically more common in the extended mesenterectomy arm (7.6% vs 1.5%; P=0.21).
“Since extended mesenterectomy is not superior to a mesenteric-sparing approach and anastomotic leakage may occur more frequently in patients undergoing extended mesenterectomy, we opt for the mesenteric-sparing approach in patients with CD undergoing primary ileocolic resection,” concluded Dr van der Does de Willebois.
- Van der Does de Willebois E, et al. Mesenteric sparing or extended mesenterectomy in primary ileocolic resection for Crohn’s disease: results of an international randomised controlled trial. OP19, 19th Congress of ECCO, 21–24 February 2024, Stockholm, Sweden.
- Coffey CJ, et al. J Crohns Colitis. 2018;12(10):1139-1150.
- Ha CWY, et al. Cell. 2020;183(3):666-683.e17.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Similar outcomes for Kono-S and side-to-side anastomosis in Crohn’s terminal ileitis Next Article
CURE-CD: Capsule endoscopy-guided proactive treatment leads to fewer relapses in Crohn’s disease »
« Similar outcomes for Kono-S and side-to-side anastomosis in Crohn’s terminal ileitis Next Article
CURE-CD: Capsule endoscopy-guided proactive treatment leads to fewer relapses in Crohn’s disease »
Table of Contents: ECCO 2024
Featured articles
Meet the Trialist: Dr Yasuharu Maeda on AI-assisted endoscopy
IL-23 Inhibitors on the Rise
VIVID-1: Mirikizumab meets expectations in Crohn’s disease
COMMAND: Long-term efficacy benefits of risankizumab in ulcerative colitis
SEQUENCE: Risankizumab versus ustekinumab across endpoints
QUASAR: Guselkumab improves QoL for patients with ulcerative colitis
Fatigue, urgency, and QoL improvements on mirikizumab in Crohn’s disease
Inspiring Drug Trials and Treatment Strategies
Novel agent VTX002 holds promise in ulcerative colitis
PROFILE: Top-down treatment strategy benefits patients with early Crohn’s disease
Biologicals and JAK inhibitors hold promise in microscopic colitis
Ustekinumab as alternative for anti-TNFs in HLA-DQA1*05-positive Crohn’s disease
How effective is dose escalation of biologicals in IBD?
Make Way for JAK Inhibitors
Promising data for JAK inhibitors in Crohn’s disease from phase 2 trial
U-ENDURE long-term extension: sustained efficacy of upadacitinib in Crohn’s disease
TRIUMPH: Tofacitinib as rescue option for acute severe ulcerative colitis
Focus on Endoscopy, Screening, and Risk Factors
Should we screen for metabolic bone disease at IBD diagnosis?
Predicting relapse in ulcerative colitis with AI-assisted endoscopy
Clear case for NUDT15 genetic testing in Asian patients with IBD
HELIOS: HD-WLE can yield similar neoplasia detection rates as HD-CE
CURE-CD: Capsule endoscopy-guided proactive treatment leads to fewer relapses in Crohn’s disease
Sharp Surgical Solutions
Extended mesenterectomy or mesenteric-sparing surgery in Crohn’s disease?
Similar outcomes for Kono-S and side-to-side anastomosis in Crohn’s terminal ileitis
Risk factors for re-resection in Crohn’s disease revealed
ADMIRE-CD-II: Darvadstrocel does not meet primary endpoint in complex peri-anal fistula
Related Articles
March 11, 2021
IBD associated with high-grade cervical neoplasia in women
May 9, 2019
OPERA II study: MAdCAM-1 antibody SHP647
May 9, 2019
HDAC6 inhibition by CKD-506
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com